| 摘要 |
<p>The present invention relates to novel sulfonyl compounds <CHEM> wherein R' and R'' are the same or different and are each hydrogen, -COCHR<4>, -COC(R<4>)3 -SO2CH3, -COOCH2CH3, -CH2-CH2-R<4>, -CONH-CH2CH2R<4>, -CONHCH2COOCH2CH3, -CH2CH2OCONH2, and R4 is Cl or a residue selected from <CHEM> -NHCOCH2CH2OH, -NHCOCH2CH3, -NHOH, -NHCH3, and <CHEM> R<1> and R<2> are the same or different and are each selected from <CHEM> 6-mercaptopurinyl, 5-fluorouracily, prednisolyl, salicyl-. hydrazidyl, 1-allyl-2-thiouracilyl, hydroxylamine, isoamidyl, or is an inorganic group consisting of -OH, -SH, -F, -J, -CCl3, or an organic group consisting of -O-CH3, -O-CH2CH3, -O-CH=CH2, -O-C6H5 or benzhydrol; or an aminoehtyl residue, or an ether group forming oxonium salts consisting of ClCH2OCH2Cl, CH3OCH2CH2OCH3, CH2ClCH2OCH2CH2Cl, C4H9OCH3, (C6H5)2O, <CHEM> (CH2=CHCH2)2O, CH2=CHOCH=CH2, C4H9OC4H9, C6H5OCH3, CH3-O-CHCl2, ClCH2-O-C2H5, OHCH2CH2-O-CH2CH2Cl, ClCH2CHCl-C2H, and Mt as a metal atom; and wherein the <CHEM> residue can optionally be changed to a linear, branched or cyclic alkyl having 1 to 6 carbon atoms, halogen or a Hg:N-(C1-C6) alkyl group. The invention further relates to a process for the preparation of the novel sulfonyl compounds and derivatives thereof, as well as for a process for manufacturing a pharmaceutical composition containing the novel sulfonyl compound as an active ingredient. Such novel sulfonyl compound are for example capable in the use for inhibitung tissue growth.</p> |
